Company intelligence / Profile preview
Lupeng Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Lupeng Pharmaceutical has multiple clinical-stage small molecule therapeutics, primarily focused on cancer and autoimmune indications. Its lead assets Rocbrutinib (LP-168) and Lacutoclax (LP-108) have reached pivotal (registration) trials in China. Rocbrutinib is now in a key registration trial for chronic spontaneous urticaria (non-oncology), while additional assets (LP-118, LP-128, NWP-0476) are advancing in early oncology trials in China, the US, and Europe. Early clinical data suggest a favorable safety and differentiated efficacy profile, especially for BTK inhibition in B-cell malignancies and autoimmune disease[1][2][3][4].
- Therapeutic areas
- OncologyInfectious DiseasesNeurologyImmunology
- Modalities
- Small moleculeProteolysis-targeting chimera therapy
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Lupeng Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lupeng Pharmaceutical.